With rivals threatening, Argenx scores key myasthenia gravis win
pharmaphorum
MARCH 23, 2022
Vyvgart (efgartigimod alfa) became the first drug in the FcRn class to be approved by the FDA last December, and despite a $225,000 annual price tag is predicted to make relatively modest sales in its IV version, which will compete with other IV gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab).
52 
Let's personalize your content